Number of patients | Univariable | ||
---|---|---|---|
HR (95%CI) | P value | ||
Age (continuous) | 53 | 1.04 (0.98–1.10) | 0.217 |
Gender | 0.724 | ||
Male | 47 | ref. | |
Female | 6 | 1.26 (0.36–4.45) | |
Histology subtype | 0.984 | ||
LUSQ | 35 | ref. | |
Non-LUSQ | 18 | 0.99 (0.41–2.37) | |
PT-MPR | 0.047 | ||
PT-MPR(-) | 22 | ref. | |
PT-MPR(+) | 31 | 0.43 (0.18–0.99) | |
mLN-RVT | 0.039 | ||
mLN-RVT 11–100% | 19 | ref. | |
mLN-RVT 0% | 28 | 0.32 (0.13–0.78) | |
mLN-RVT 1–10% | 6 | 0.42 (0.11–1.61) | |
mLN-MPR | 0.011 | ||
mLN-MPR(-) | 19 | ref. | |
mLN-MPR(+) | 34 | 0.34 (0.14–0.78) | |
mLN-MPR/PT-MPR response pattern | 0.030 | ||
mLN-MPR(-)/PT-MPR(-) | 10 | ref. | |
mLN-MPR(-)/PT-MPR(+) | 9 | 0.45 (0.12–1.66) | |
mLN-MPR(+)/PT-MPR(-) | 12 | 0.35 (0.11–1.08) | |
mLN-MPR(+)/PT-MPR(+) | 22 | 0.21 (0.08–0.61) | |
pN stage | 0.036 | ||
N2-N1 | 25 | ref. | |
N0 | 28 | 0.40 (0.17–0.94) | |
pN stage/PT-MPR response pattern | 0.117 | ||
pN2-N1/PT-MPR(-) | 13 | ref. | |
pN2-N1/PT-MPR(+) | 12 | 0.73 (0.24–2.21) | |
pN0/PT-MPR(-) | 9 | 0.70 (0.22–2.28) | |
pN0/PT-MPR(+) | 19 | 0.24 (0.07–0.76) | |
Adjuvant treatment | 0.178 | ||
No | 13 | ref. | |
Yes | 40 | 0.55 (0.23–1.32) |